DE602006016085D1 - Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor - Google Patents

Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor

Info

Publication number
DE602006016085D1
DE602006016085D1 DE602006016085T DE602006016085T DE602006016085D1 DE 602006016085 D1 DE602006016085 D1 DE 602006016085D1 DE 602006016085 T DE602006016085 T DE 602006016085T DE 602006016085 T DE602006016085 T DE 602006016085T DE 602006016085 D1 DE602006016085 D1 DE 602006016085D1
Authority
DE
Germany
Prior art keywords
egfr kinase
methods
kinase inhibitors
inhibitors
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006016085T
Other languages
English (en)
Inventor
John D Haley
Graeme Griffin
Lukas C Amler
David A Eberhard
Robert L Yauch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
OSI Pharmaceuticals LLC
Original Assignee
Genentech Inc
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, OSI Pharmaceuticals LLC filed Critical Genentech Inc
Publication of DE602006016085D1 publication Critical patent/DE602006016085D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
DE602006016085T 2005-03-16 2006-03-16 Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor Active DE602006016085D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66254505P 2005-03-16 2005-03-16
US67182105P 2005-04-15 2005-04-15
PCT/US2006/009403 WO2006101925A2 (en) 2005-03-16 2006-03-16 Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors

Publications (1)

Publication Number Publication Date
DE602006016085D1 true DE602006016085D1 (de) 2010-09-23

Family

ID=36586095

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006016085T Active DE602006016085D1 (de) 2005-03-16 2006-03-16 Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor

Country Status (7)

Country Link
US (3) US8093011B2 (de)
EP (1) EP1861715B1 (de)
JP (1) JP5085529B2 (de)
AT (1) ATE477495T1 (de)
CA (1) CA2601157A1 (de)
DE (1) DE602006016085D1 (de)
WO (1) WO2006101925A2 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
US8017321B2 (en) * 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
EP1751309B1 (de) * 2004-05-27 2015-07-22 The Regents of The University of Colorado Methoden zur Vorhersage des klinischen Verlaufs von mit EGFR Inhibitoren behandelten Krebspatienten
KR20150008926A (ko) * 2005-03-11 2015-01-23 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는 히스톤 데아세틸라제 억제제
DE602006016085D1 (de) 2005-03-16 2010-09-23 Genentech Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
ES2374450T3 (es) * 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
CN101677977A (zh) * 2006-11-10 2010-03-24 欣达克斯制药公司 用于治疗癌症的ERα+配体和组蛋白脱乙酰化酶抑制剂组合
KR100934706B1 (ko) * 2006-12-07 2009-12-31 재단법인서울대학교산학협력재단 Ｔｍ４ｓｆ５의 기능을 저해하는 항암물질의 스크리닝 방법및 칼콘계 화합물을 함유하는 항암조성물
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
EP2134860A1 (de) * 2007-04-13 2009-12-23 OSI Pharmaceuticals, Inc. Biologische marker als prädiktoren der antikrebsreaktion auf kinasehemmer
AU2008276251B2 (en) * 2007-07-13 2014-04-24 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
US20100298270A1 (en) * 2007-07-23 2010-11-25 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
ES2477294T3 (es) * 2007-08-13 2014-07-16 Baxter International Inc Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson
JP2010535518A (ja) * 2007-08-14 2010-11-25 エフ．ホフマン−ラ ロシュ アーゲー Ｅｇｆｒ阻害剤治療のための予測マーカー
JP2010535517A (ja) 2007-08-14 2010-11-25 エフ．ホフマン−ラ ロシュ アーゲー Ｅｇｆｒ阻害因子治療のための予測マーカー
BRPI0815545A2 (pt) 2007-08-14 2015-02-10 Hoffmann La Roche Marcadores preditivos para o tratamento com inibidores de egfr
BRPI0817361A2 (pt) * 2007-08-14 2015-03-31 Hoffmann La Roche Marcador preditivo para tratamento com inibidor de egfr
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
EP2036576A1 (de) * 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B-Fibronektin als Stratifizierungsmarker für Antitumormittel
US7939272B2 (en) 2007-10-03 2011-05-10 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2694356A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2207892A4 (de) 2007-10-15 2010-12-08 Precision Therapeutics Inc Verfahren zur selektion aktiver agentien für die krebsbehandlung
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
EP2071336A1 (de) * 2007-12-13 2009-06-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Serumproteom zum Finden von diagnostischen Markern und zur Überwachung des therapeutischen Eingriffs bei der Behandlung von Leberzellenkarzinom
TW200940064A (en) * 2008-03-06 2009-10-01 Genentech Inc Combination therapy with C-MET and EGFR antagonists
US7998688B2 (en) * 2008-03-07 2011-08-16 OSI Pharmaceuticals, LLC Inhibition of EMT induction in tumor cells by anti-cancer agents
US7951549B2 (en) * 2008-03-07 2011-05-31 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20110191868A1 (en) * 2008-04-10 2011-08-04 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
EP2281027A4 (de) * 2008-05-14 2011-07-27 Precision Therapeutics Inc Verfahren zur vorhersage der reaktion eines patienten auf egfr-hemmer
US20100311084A1 (en) * 2008-05-14 2010-12-09 Precision Therapeutics, Inc. Methods for predicting a patient's response to egfr inhibitors
US20110171124A1 (en) * 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401613A2 (de) * 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
US8642834B2 (en) * 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2419522A4 (de) * 2009-04-17 2012-10-31 Glen Weiss Verfahren und kits zur prognose des therapieergebnisses von tyrosinkinasehemmern
US20120142028A1 (en) * 2009-04-17 2012-06-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
AU2011223655A1 (en) * 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120095029A1 (en) * 2010-10-15 2012-04-19 Hoffmann-La Roche Inc. Ipp complex as marker for erlotinib treatment
US20140155397A1 (en) * 2011-04-01 2014-06-05 Board Of Regents Emt signatures and predictive markers and method of using the same
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2012167278A1 (en) * 2011-06-02 2012-12-06 Almac Diagnostics Limited Molecular diagnostic test for cancer
EP2751285B2 (de) 2011-08-31 2020-04-01 Genentech, Inc. Methode zur bestimmung der empfindlichkeit eines tumors für egfr kinase-inhibitoren
KR20140066783A (ko) 2011-09-30 2014-06-02 제넨테크, 인크. 종양 또는 종양 세포에서의 상피 또는 중간엽 표현형 및 egfr 키나제 억제제에 대한 반응의 진단 메틸화 마커
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
MX2014010265A (es) 2012-02-28 2015-06-23 Novartis Ag Seleccion de pacientes con cancer para administracion de inhibidores de señalizacion de wnt utilizando estado de mutacion de rnf43.
EP3441767B1 (de) * 2012-03-28 2021-02-24 On-chip Biotechnologies Co., Ltd. Vorrichtung zur erkennung des malignitätsgrades einer zirkulierenden tumorzelleneinheit und kit dafür
BR112014032728A2 (pt) 2012-06-27 2017-11-28 Berg Llc uso de marcadores no diagnóstico e tratamento de câncer de próstata
WO2014043633A1 (en) * 2012-09-17 2014-03-20 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
WO2014074805A1 (en) 2012-11-08 2014-05-15 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US10011574B2 (en) 2012-11-21 2018-07-03 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014087156A1 (en) 2012-12-03 2014-06-12 Almac Diagnostics Limited Molecular diagnostic test for cancer
US11089959B2 (en) 2013-03-15 2021-08-17 I2Dx, Inc. Electronic delivery of information in personalized medicine
US9782075B2 (en) 2013-03-15 2017-10-10 I2Dx, Inc. Electronic delivery of information in personalized medicine
EP3091971A1 (de) * 2014-01-08 2016-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur vorbeugung oder verminderung von metastatischer verbreitung
KR20160127149A (ko) 2014-03-21 2016-11-02 아지오스 파마슈티컬스 아이엔씨. 화합물 및 이의 사용 방법
MA39776A (fr) 2014-03-24 2017-02-01 Hoffmann La Roche Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
US10539566B2 (en) 2014-12-08 2020-01-21 Berg Llc Use of markers including filamin A in the diagnosis and treatment of prostate cancer
WO2017104821A1 (ja) 2015-12-18 2017-06-22 日本ゼオン株式会社 浮遊培養馴化接着型細胞の調製方法、接着型上皮細胞の上皮間葉転換誘導方法、及びそれらの利用
JP6789512B2 (ja) * 2016-05-10 2020-11-25 学校法人日本医科大学 肺癌治療のための抗癌剤の効果の検査法
EP3764902A4 (de) * 2018-03-13 2021-12-08 I2Dx, Inc. Elektronische bereitstellung von informationen in der personifizierten medizin
CN113312056B (zh) * 2021-06-16 2022-04-19 浪潮云信息技术股份公司 angular大型集成项目的国际化实现方法、电子设备及存储介质

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
US5925519A (en) * 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
ATE292623T1 (de) 1997-05-07 2005-04-15 Sugen Inc 2-indolinonderivate als modulatoren der proteinkinase-ativität
AU8816298A (en) 1997-08-22 1999-03-16 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
AU9454198A (en) 1997-11-11 1999-05-31 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6395734B1 (en) 1998-05-29 2002-05-28 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
ES2161655B1 (es) 1999-07-01 2002-06-01 Consejo Superior Investigacion Procedimiento para determinar la capacidad invasiva y metastasica de un tumor epitelial mediante el uso de snail.
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
WO2003062395A2 (en) 2002-01-18 2003-07-31 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
DK1918386T3 (da) 2002-03-13 2012-01-02 Genomic Health Inc Genekspressionsprofiler i biopsier af tumorvæv
AU2003241898A1 (en) * 2002-06-03 2003-12-19 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
ATE547708T1 (de) 2002-06-05 2012-03-15 Cedars Sinai Medical Center Verfahren zur handhabung der kinasehemmertherapie
WO2004000102A2 (en) 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US8008003B2 (en) 2002-11-15 2011-08-30 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
CA2512536A1 (en) 2003-01-08 2004-07-29 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2004065602A1 (es) 2003-01-17 2004-08-05 Universidad Autónoma de Madrid Procedimiento para identificar la transición epitelio-mesenquimal de células mesoteliales (temcm) e identificar compuestos moduladores de temcm, composiciones farmacéuticas y su uso en el diagnóstico y tratamiento de enfermedades que cursan con temcm
EP1590487A2 (de) 2003-02-06 2005-11-02 Genomic Health, Inc. Genexpressionsmarker für die antwort auf egfr-inhibitormedikamente
JP3762975B2 (ja) * 2003-03-18 2006-04-05 学校法人慶應義塾 単球由来多能性細胞ｍｏｍｃ
WO2004111273A2 (en) 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP1664716A4 (de) 2003-08-15 2008-08-13 Smithkline Beecham Corp Krebs-biomarker
CA2552658A1 (en) 2004-01-07 2005-07-28 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US8017321B2 (en) 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
EP1735463A4 (de) 2004-03-26 2008-10-15 Bristol Myers Squibb Pharma Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren von epidermalem wachstumsfaktor-rezeptor in nicht-kleinzelligem lungenkrebs
WO2005107803A2 (en) 2004-05-06 2005-11-17 Vernalis Plc Methods of determining the prognosis and treatment of subjects with lung cancer
EP1751309B1 (de) 2004-05-27 2015-07-22 The Regents of The University of Colorado Methoden zur Vorhersage des klinischen Verlaufs von mit EGFR Inhibitoren behandelten Krebspatienten
KR20150008926A (ko) 2005-03-11 2015-01-23 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는 히스톤 데아세틸라제 억제제
DE602006016085D1 (de) 2005-03-16 2010-09-23 Genentech Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
EP1929306A4 (de) 2005-09-01 2009-11-11 Precision Therapeutics Inc Chemosensible assays, die tumorzellen mit persistenten phänotypischen merkmalen
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
EP2134860A1 (de) 2007-04-13 2009-12-23 OSI Pharmaceuticals, Inc. Biologische marker als prädiktoren der antikrebsreaktion auf kinasehemmer
AU2008221604B2 (en) 2008-09-22 2010-04-22 Commonwealth Scientific And Industrial Research Organisation Temperature-responsive polymer particles in protein separation applications
US20120142028A1 (en) 2009-04-17 2012-06-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors

Also Published As

Publication number Publication date
US9244058B2 (en) 2016-01-26
WO2006101925A3 (en) 2007-02-01
EP1861715B1 (de) 2010-08-11
WO2006101925A2 (en) 2006-09-28
US20120157480A1 (en) 2012-06-21
EP1861715A2 (de) 2007-12-05
US20060211060A1 (en) 2006-09-21
CA2601157A1 (en) 2006-09-28
US20160158235A1 (en) 2016-06-09
JP2008533490A (ja) 2008-08-21
ATE477495T1 (de) 2010-08-15
US8093011B2 (en) 2012-01-10
JP5085529B2 (ja) 2012-11-28

Similar Documents

Publication Publication Date Title
DE602006016085D1 (de) Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
ATE533057T1 (de) Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
WO2008127718A3 (en) Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2009045389A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009045361A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
Nie et al. Long non‐coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival
Gazzaniga et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis
Dickson et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer
Rossé et al. Control of MT1-MMP transport by atypical PKC during breast-cancer progression
Adler et al. Metastatic pathways in patients with cutaneous melanoma
DE602005019294D1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
Grupp et al. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence
Luo et al. Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma
Sun et al. HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases
Torrisi et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17
Gioacchini et al. The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma
Yang et al. Overexpression of the cancer stem cell marker CD117 predicts poor prognosis in epithelial ovarian cancer patients: Evidence from meta-analysis
Zhang et al. Overexpression of ubiquitin specific peptidase 14 predicts unfavorable prognosis in esophageal squamous cell carcinoma
Curtit et al. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay
Dai et al. Ubiquitin-specific peptidase 22, a histone deubiquitinating enzyme, is a novel poor prognostic factor for salivary adenoid cystic carcinoma
Liu et al. MicroRNA‑10b expression in node‑negative breast cancer‑correlation with metastasis and angiogenesis
Lee et al. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer
Qiao et al. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer
Song et al. Combined detection of HER2, Ki67, and GSTP1 genes on the diagnosis and prognosis of breast cancer
Ma et al. Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion